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Hepatitis  B virus  (HBV)  infection  is  a worldwide  disease  associated  with  signiﬁcant  morbidity  and  mor-
tality  and  after  acute  infection,  HBV  infection  can persist  in about  1-2%  of immunocompetent  hosts.
Chemotherapy-induced  immunosuppression  can  lead  to  HBV  reactivation  and  may  cause  discontinua-
tion  of  anticancer  treatment,  fulminant  hepatitis  with  liver  failure  and  death.  During  immunosuppressive
treatments  such  as chemotherapy,  reactivation  of  HBV  infection  is  a life-threatening  complication  that
can occur  in HBV  active  or  inactive  carriers  but  also  in  patients  with  OBI. Occult  HBV  infection  (OBI)
is  deﬁned  as  the presence  of  detectable  very  low  levels  of  HBV  DNA  in  HBsAg-negative  patients.  Manyhemotherapy
mmunosuppression
eactivation
BV
literature  data  showed  a  beneﬁt  from  prophylactic  antiviral  treatment  in  cancer patients  at  risk for  HBV
reactivation,  however  there  is no  evidence  in determining  the  beneﬁt  of  routine  screening  for  chronic
HBV  infection  in all patients  undergoing  cytotoxic  and  immunosuppressive  chemotherapy.  Major  guide-
lines  recommend  HBV  screening  in  HBV-infection  high  risk  patients  or if  the  immunosuppression  caused
by  the treatment  is  expected  to  be high.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Hepatitis B and cancer: numbers and burden of disease
Hepatitis B virus (HBV) infection is a worldwide problem associ-
ted with signiﬁcant morbidity and mortality. It has been estimated
hat two billion people have had hepatitis B virus exposure and
ear 400 million have experienced chronic infection (Sagnelli et al.,
012). After acute hepatitis, HBV infection persists in about 1–2%
∗ Corresponding author at: Department of Oncology, University Hospital of Udine,
iazzale S.M. Misericordia 1, Udine, Italy.
E-mail address: bozza.claudia@gmail.com (C. Bozza).
ttp://dx.doi.org/10.1016/j.critrevonc.2015.10.017
040-8428/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
of immunocompetent hosts and in higher percentage of immuno-
suppressed patients (Lavanchy, 2005).
The chronic infection increases the risk of developing cirrhosis
and hepatocellular carcinoma up to 40% (McQuillan et al., 1999; De
Jongh et al., 1992). Moreover, HBV-carrier patients could present,
during their course of life, other malignancies unrelated to hepatitis
viruses for which chemotherapy treatment is indicated. Further-
more, chemotherapy-induced immunosuppression can lead to HBV
reactivation and may  cause hepatitis and liver failure, discontinu-
ation of anticancer treatment and death.
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Malignant cancer is a worldwide disease and in developed coun-
ries one in three people will develop cancer during their lifetimes
Torre et al., 2015).
In cancer patients, over the last decades, chemotherapy has
emonstrated a signiﬁcant role in achieving cancer recovery and
rolonging survival. The HBV reactivation during anticancer treat-
ent can results in life-threatening events and in poor outcome
ue to early discontinuation of chemotherapy.
In clinical practice, the oncologists deal with a large number of
atients undergoing anticancer treatments and with the uncertain-
ies about screening and prophylaxis against HBV.
The aim of this review is to provide a practical and concise guide
or the medical oncologist about diagnosis, deﬁnitions, screening
nd management of HBV infection in cancer patients.
. Hepatitis B infection: several ways to wear a mask
The pathogenesis and clinical manifestations of hepatitis B
nfection are due to the interaction between the virus replication
nd the host’s immune system response, especially lymphocyte lin-
age. The immunologic reaction causes liver injury and, if impaired
r tolerant, can result in chronic hepatitis (Jung et al., 1994; Chisari,
997). Five stages can be identiﬁed in the viral life cycle of HBV
Torres and Davila, 2012; Hoofnagle, 2009).
The immune tolerance stage represents the incubation period.
The virus replicates without a deep activation of immune sys-
tem, often with normal levels of serum alanine aminotransferase
(ALT).
The immune active stage is an inﬂammatory reaction with hep-
atocyte necrosis. In patients with acute infection the duration of
this stage is approximately one month and is accompanied by
a variety of symptoms. In chronic infections this phase can last
over ten years before onset of cirrhosis, immune clearance phase
taking place or hepatocellular carcinoma development.
The inactive chronic infection consists in low or non-measurable
viral replication and serum ALT levels within the normal range.
During this phase the integration of viral genome into hepatocyte
genetic code could take place.
Chronic disease can result from the inactive chronic infection
phase or from immune active stage.
Recovery is the disease stage in which virus can not be detected
in the blood and antibodies to viral antigens are produced.
HBV infection is associated with characteristic changes in the
erum levels of hepatitis B antigens and antibodies and these
arkers are useful to deﬁne different clinical stages of disease
Figs. 1 and 2).
Hepatitis B surface antigen (HBsAg) is the serologic hallmark of
BV infection; it appears in serum during the incubation period,
fter 1–10 weeks the acute exposure to HBV and prior to the onset
f hepatitic symptoms or elevation of serum ALT. In patients who
ecovered from the infection, HBsAg is undetectable after a period
f four to six months. On the other hand, the persistence of the
arker for more than six months reveals a chronic infection.
The disappearance of HBsAg is followed by the appearance of
epatitis B surface antibodies (anti-HBs). In most patients, anti-HBs
onfer long-term immunity and often a lifelong one. In some cases,
here is a window period of several weeks during which neither
BsAg nor anti-HBs can be detected in the serum. On the other
and, in 24% of HBsAg positive patients, HBsAg and anti-HBs can
oexist but these antibodies are unable to neutralize the circulating
iruses (Tsang et al., 1986).
Hepatitis B core antigen (HBcAg) is not detectable in the serum
ecause is an intracellular antigen of infected hepatocytes.gy/Hematology 98 (2016) 137–146
Hepatitis B core antibodies (anti-HBc) appear at the onset of
symptoms in acute infection and may  persist lifelong. The presence
of anti-HBc suggests previous or ongoing HBV infection: during the
acute phase anti-HBc are predominantly of IgM class and, notably,
IgM anti-HBc are the markers of HBV infection during the win-
dow period cited above. IgM anti-HBc may  be detectable after the
recovery from acute infection for a period up to two  years and they
increase during exacerbations of chronic hepatitis B (Maruyama
et al., 1994). IgG anti-HBc persist in association with anti-HBs in
patients who  recovered from acute hepatitis B and they also persist
along with HBsAg in those who  develop chronic HBV infection.
Hepatitis B e antigen (HBeAg) is a secretory protein generally
considered a marker of HBV replication and infectivity. The pres-
ence of HBeAg is usually associated with high levels of HBV DNA in
the serum and higher rates of HBV transmission. In patients with
acute infection the seroconversion from HBeAg to hepatitis B e
antibodies (anti-HBe) occurs early, prior to HBsAg to anti-HBs sero-
conversion; however, HBeAg seroconversion may  be postponed for
many years in patients with chronic HBV infection, often reveal-
ing active liver disease and high serum levels of HBV DNA. The
seroconversion from HBeAg to anti-HBe is usually related with a
decrease in serum HBV DNA and often with a remission of liver
disease (Hoofnagle et al., 1981; Realdi et al., 1980).
When patients recover from acute hepatitis, serum levels of HBV
DNA disappear when determined by hybridization or bDNA assays,
but they could remain detectable if tested by PCR assays (Carman
et al., 1989). This fact suggests that HBV, even if a patient recovers
from infection, may  persist in the host controlled by the immune
system. HBV DNA is a major instrument for the assessment of viral
replication that is in turn the principle criteria inﬂuencing the clin-
ical decision about the timing of antiviral therapy and response
evaluation to treatment.
3. How many types of hepatitis are there? Navigating a sea
of deﬁnitions
Chronic hepatitis B: Chronic necroinﬂammatory disease of the
liver caused by HBV persistent infection. Serological marker of
chronic infection is HBsAg persisting more than six months; more-
over, it can be divided in HBeAg-positive and negative forms.
Active HBsAg carrier: A patient presenting HBsAg in serum is con-
sidered HBV active carrier in the presence of HBeAg or anti-HBe and
HBV DNA >20000 UI/mL.
Inactive HBsAg carrier: A patient presenting HBsAg in serum
is considered HBV inactive carriers if HBeAg is absent, anti-HBe
present and HBV DNA <20000 UI/mL.
Occult HBV carrier: HBsAg-negative patient presenting HBV DNA
in the liver, with undetectable or very low (<200 UI/mL) HBV DNA
in the serum.
Resolved hepatitis B: Previous HBV infection without virological,
biochemical, or histological evidence of virus infection.
Window period:  Time between the disappearance of HBsAg and
the appearance of anti-HBs. It takes place in several weeks or
months and the serological diagnosis can be made by the detection
of anti-HBc IgM.
Acute exacerbation or ﬂare of hepatitis B: An abrupt increase in
serum aminotransferase levels with or without symptoms of hep-
atitis in a patient with underlying chronic liver disease.
Reactivation of hepatitis B: Reappearance of necroinﬂammatory
disease of the liver in an inactive HBsAg carrier or in a patient
with a resolved hepatitis B. In occult infection, the conversion of
serum HBV DNA test from negative to positive or the reappearance
of HBsAg are signs of reactivation.
HBeAg clearance: Disappearance of HBeAg serum levels in a pre-
viously HBeAg-positive patient.
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Fig. 1. Antigens and antibodies proﬁle in acute HBV infection.
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HBeAg seroconversion:  Disappearance of HBeAg serum levels and
ppearance of anti-HBe.
. HBV serology: unravelling the puzzle
Serologic tests for HBV antigens and antibodies are useful in
onﬁrming the diagnosis of HBV infection, in selecting patients for
ntiviral treatment and in the evaluation of the response to treat-
ent. The following table shows the interpretation of serological
ests for HBV (Table 1).
The diagnosis of acute hepatitis is characterized by the serum
etection of HBsAg and anti-HBc IgM; in the initial phase of infec-
ion, HBeAg and HBV DNA are also present. Recovery phase is
ccompanied by the disappearance of HBV DNA, the seroconversion
rom HBeAg to anti-HBe and subsequently from HBsAg to anti-HBs.
When HBsAg-positive acute hepatitis is suspected clinicians
ave to consider potential differential diagnosis such as acute hep-
titis B, exacerbations of chronic hepatitis B, reactivation of occult
epatitis B, superinfection of a HBV carrier with other hepatitis
iruses (Chu et al., 1989) and acute exotoxic hepatitis in a HBV
arrier.
Previous HBV infection is characterized by the presence of anti-
Bs and antiHBc IgG. Acquired immunity due to vaccination isndicated by the presence of the only anti-HBs.
The diagnosis of chronic HBV infection is based upon the persis-
ence of HBsAg for more than six months. The inactive carrier state
s characterized by normal ALT levels, absence of HBeAg, presenceﬁle in chronic HBV infection.
of anti-HBe, and HBV DNA levels <2000 UI/mL. Active carrier state
is determined by high viral load (>20000 UI/mL), whereas HBeAg
could be present or absent with anti-HBe positivity (Marcellin et al.,
1990).
Occult HBV infection (OBI) is deﬁned as the presence of
detectable very low levels of HBV DNA in HBsAg-negative patients.
OBI may  be observed in the window period during acute HBV infec-
tion, in the absence of HBsAg and anti-HBs (isolated anti-HBc), or
in others conditions linked to immunodepression, such as HIV  and
HCV infection or pharmacological immunosuppression (Sagnelli
et al., 2014).
The isolated serological presence of anti-HBc in the absence of
HBsAg and anti-HBs has been reported in less than 2% of healthy
volunteers in low HBV prevalence areas and up to 20% of endemic
areas population (Lok et al., 1988). This serological condition can
occur in three different situations:
• during the window period of acute hepatitis B
• after recovery from acute hepatitis B when anti-HBs has fallen to
undetectable levels
• after many years of chronic HBV infection when HBsAg may  be
undetectable because the loss of HBsAg. This ﬁnding occurs in
0.5% of chronic hepatitis B patients per year.The clinical signiﬁcance of isolated anti-HBc is unclear, therefore
clinicians should repeat serologic testing for HBsAg, anti-HBs, anti-
HBc, anti-HBe. If these tests are negative, anti-HBc IgM should be
140 C. Bozza et al. / Critical Reviews in Oncology/Hematology 98 (2016) 137–146
Table  1
Interpretation of HBV serology.
HBsAg Anti-HBc Anti-HBs IgM anti-HBc
Susceptible patient Negative Negative Negative –
Previously infected patient Negative Positive Positive –
Vaccinated patient Negative Negative Positive –
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Unclear interpretation Negative 
ested to rule out window period of acute infection. The detection
f anti-HBc could be also a false positive ﬁnding. In this case HBV
NA determination could be considered in order to ﬁnd chronic
nfection with low viral load.
. HBV reactivation during chemotherapy: clouds on the
orizon
During immunosuppressive treatments such as chemotherapy,
eactivation of HBV infection is a life-threatening complication that
an occur in HBV active or inactive carriers and in patients with OBI.
In fact, after exposition to HBV the virus can persist in the
ody even after serological recovery from acute hepatitis. HBsAg-
ositive patients receiving chemotherapy have a higher risk of
eactivation that range approximately from 20 to 50% (Yeo et al.,
004a; Hsu et al., 2014).
Reactivation of HBV infection was ﬁrst described referring to
reatments of hematological disease, such as anti-CD20 monoclonal
ntibodies (Seto et al., 2014), CHOP regimen (cyclophosphamide,
oxorubicin, vincristine and prednisone) (Hsu et al., 2014) or ﬂu-
arabine (Dominguez et al., 2015).
Nevertheless, an increasing number of cases have been
escribed among patients treated with chemotherapy for solid
umors giving evidence of HBV reactivation in these cases.
In particular, patients undergoing chemotherapy for breast can-
er have higher rate of HBV reactivation (41–56%) than other cancer
atients (14–21%) (Liu et al., 2015; Yeo et al., 2003). In addition,
ore patients with reactivation undergo permanent discontinu-
tion or delay of treatment (76%) compared with those without
vidence of reactivation (33%) (Yeo et al., 2003).
HBV reactivation is characterized by an important early
nhancement of viral replication after the start of chemotherapy
ith spread of HBV to hepatocytes and rising serum HBV DNA lev-
ls. These modiﬁcations can occur up to three weeks earlier than
aboratory alterations and can be accompanied by serological reap-
earance of HBeAg and HBsAg (seroreversion). In a subsequent
hase, after chemotherapy withdrawal, the immunological func-
ion is restored leading to cytotoxic-T-cells mediated destruction
f HBV infected hepatocytes. This results in increasing ALT levels
hepatic ﬂare) and may  cause several clinical manifestations that
an range from asymptomatic self-limiting hepatitis to fulminant
epatic failure or even death. During this phase, HBV DNA levels
ay  decrease.
There is not a deﬁned consensus about the deﬁnition of HBV
are. Frequently, it is described an increase in serum ALT higher
han 5 times the upper limit of normal or more than 3 times the
aseline value, whichever was higher (Perrillo et al., 2015; Lok et al.,
987).
Because of severe hepatic ﬂares may  be characterized by
ncreased anti-HBc IgM, the risk of misdiagnosis of acute hepatitis
 in unknown HBsAg positive-patient is relevant. Clinical history,
igher titers of anti-HBc IgM and a lower viral load can help the
linician in differential diagnosis between acute hepatitis B and a
are of chronic infection.
Moreover, also other factors such as drugs, superinfections with
ther hepatitis viruses, tumor inﬁltration and systemic infectionsositive Negative Positive
ositive Negative Negative
ositive Negative –
can cause an increase of ALT levels and should be considered in the
clinical decision-making.
In the third stage of reactivation, liver injury is recovered and
virus markers normalize.
The risk of HBV reactivation in cancer patients receiving
chemotherapy is inﬂuenced by predisposing factors related to
the virus, the host and speciﬁc immunosuppressive treatment,
although the complete magnitude of risk is unknown.
Viral factors are represented by HBsAg and HBeAg seropositiv-
ity, the presence of B genotype of the virus and above all by a high
HBV DNA level (>105ˆ copies/mL); host predisposing factors are
male sex, young age, high ALT serum levels at baseline and absence
or decrease of anti-HBs levels during the anticancer treatment (Yeo
et al., 2003; Lau et al., 2002; Yeo et al., 2004b).
The type of chemotherapy and the concomitant use of gluco-
corticoids are other risk factors; notably, the use of anthracyclines,
cyclophosphamide and vinca alkaloids is associated with an
increased risk of reactivation (Yeo et al., 2004b). In particular, epiru-
bicin seems to upregulate the in vitro HBV replication levels and
the pathological effects of HBV (Xu et al., 2014). It follows that the
chemotherapy combination AC (doxorubicin-cyclophosphamide)
in the adjuvant setting of breast cancer is one of the most predis-
posing therapeutic regimen for HBV reactivation.
The association with HBV reactivation is reported also for gem-
citabine (Cheong et al., 2003) and everolimus, one of the targeted
therapies approved for breast cancer treatment (Sezgin et al., 2013).
6. Prophylaxis and treatment of HBV reactivation: the state
of the art
For managing a possible HBV reactivation during chemotherapy,
the clinician could adopt two  different strategies: to employ a pro-
phylactic treatment for high risk patients or to prescribe an antiviral
therapy when reactivation is detected. However, the second strat-
egy could lead to an early discontinuation of chemotherapy and
it does not usually stop liver damage caused by viral reactivation
(Yun et al., 2011; Yeo et al., 2004c).
Lamivudine, an oral nucleoside reverse transcriptase inhibitor,
is indicated in treatment of chronic hepatitis B associated with
evidence of viral replication and active liver inﬂammation.
Many literature data showed a beneﬁt from prophylactic antivi-
ral treatment in cancer patients at risk for HBV reactivation (Hsu
et al., 2014; Leaw et al., 2004; Martyak et al., 2008; Loomba et al.,
2008). Most of the studies were limited on preventive use of lamivu-
dine and based on hematologic patients, however few studies were
conducted on patients with solid tumors, especially with breast
cancer.
A meta-analysis of 14 studies involving 275 patients undergoing
chemotherapy for hematological or solid malignancies found that
prophylactic lamivudine reduced the risk of HBV reactivation and
the incidence and severity of HBV-related hepatitis by 80–100%
(Loomba et al., 2008).Referring to breast cancer, Sohn et al. (2011) analyzed the
efﬁcacy of pre-emptive use of lamivudine in 169 HbsAg positive-
patients receiving anthracycline-based adjuvant chemotherapy.
They found that prophylactic lamivudine seems to reduce the
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everity of hepatic dysfunction and the incidence of hepatitis
are-up during chemotherapy compared with patients receiving
herapeutic antiviral treatment at the onset of increasing liver
nzymes.
A more recent metanalysis (Liu et al., 2015) regarding HBsAg-
ositive breast cancer patients demonstrated that lamivudine
rophylaxis had a signiﬁcant reduction in the risk of HBV
eactivation (RR = 0.23, 95% CI: 0.13–0.39, p < 0.00001) and the
ates of moderate and severe hepatitis were signiﬁcantly lower
han the patients group with no prophylaxis (RR = 0.25, 95% CI:
.1–0.62, p < 0.003; RR = 0.25, 95% CI: 0.1–0.59, p < 0.0002). Further-
ore, patients in lamivudine-prophylaxis group presented fewer
hemotherapy disruptions and delays (RR = 0.36, 95% CI: 0.21–0.64,
 = 0.0004; RR = 0.42, 95% CI: 0.21–0.82, p = 0.01).
There is clinical evidence that reserving the use of lamivudine
n patients who develop ALT elevation due to HBV reactivation is
ot effective compared to prophylactic strategy. This ﬁnding can
e explained by the biology of viral reactivation: studies suggested
hat viral replication occurs 1–2 weeks before hepatitis ﬂare (Liaw,
003; Yeo and Johnson, 2006; Yeo et al., 2001; Lau et al., 2003;
ohrt et al., 2006), so the prophylactic use of lamivudine have a clin-
cal stronger rational than therapeutic strategy. In these patients,
espite use of lamivudine, the reported mortality is in the range of
0–30% (De la Revilla et al., 2013).
During chemotherapy, when hepatitis B ﬂare is detected, antivi-
al treatment should be started as soon as possible because the
ffects of antiviral therapy are not immediate on the liver damage.
An important concern related to the use of lamivudine is the
otential development of lamivudine-resistance mutation (YMDD-
utations), related to high HBV DNA levels (Torres and Davila,
012) at baseline and associated with clinical and biochemical ﬂare
Tan et al., 2015). Because of this resistance, lamivudine could be
neffective to prevent HBV reactivation and hepatitis, so that it is
ppropriate to avoid this drug and use other ones in patients who
eed extended periods of chemotherapy. Indeed, newer antiviral
rugs such as entecavir, tenofovir, adefovir and telbivudine are now
vailable. Experts recommended the use of lamivudine or telbivu-
ine if the duration of treatment is no longer than 12 months and
BV DNA levels at baseline are low. On the other hand, entecavir
Watanabe et al., 2010) or tenofovir should replace lamivudine for
atients who require longer duration of prophylaxis (more than 12
onths) or have higher HBV DNA titers (De la Revilla et al., 2013).
On the basis of recent guidelines (European Association For
he Study Of The Liver, 2012), the prophylactic treatment of
BsAg-positive patients depends on HBV- DNA load: if <2000 UI/mL
nd the patient is going to receive a conventional chemotherapy
amivudine could be prescribed. The prophylactic employment of
ntecavir or tenofovir should be reserved to hematological patients
ndergoing stem-cell transplantion or monoclonal antibody ther-
py and in case of HBV-DNA load >2000 UI/mL.
. Occult HBV infection: the hidden enemy
The prevalence of occult HBV infection (OBI) varies from 1% to
5% worldwide, according to endemicity, cohort factors and sensi-
ivity of diagnostic techniques (Raimondo et al., 2008).
OBI is characterized by the presence of HBV DNA in liver tissue
ith undetectable or very low (<200 UI/ml) serum levels in HBsAg-
egative patients (Kwak and Kim, 2014). We  can classify OBI into
eropositive (anti-HBc and/or anti-HBs positive) and seronegative
absence of anti-HBc and anti-HBs) group (Squadrito et al., 2014;
oppola et al., 2013; Hu, 2002; Bréchot et al., 1998; Dos et al., 2014;
orbenson and Thomas, 2002; Raimondo et al., 2013).
The extraction of HBV DNA from the liver tissue would be
he gold standard for diagnosis of occult HBV infection. However,gy/Hematology 98 (2016) 137–146 141
serum HBV DNA assay is the most commonly used method for diag-
nosis, because of the better feasibility in routine clinical practice
despite serum DNA is sometimes undetectable (Raimondo et al.,
2008).
In OBI carriers patients, HBV reactivation represents a relevant
clinical implication, particularly in immunosuppressed patients
such as cancer ones; OBI reactivation could cause liver failure, lead-
ing to chemotherapy discontinuation with consequent progression
of the disease, fulminant hepatitis and life-threatening conditions
too (Schmeltzer and Sherman, 2010; Coppola et al., 2011). The
highest risk of OBI reactivation occurs in hematologic patients, in
liver and hematopoietic stem cell transplantation or in anti-CD20-
treated patients (Squadrito et al., 2014; Raimondo et al., 2007;
Pei et al., 2010). Regarding solid tumors, there are not conclusive
studies about HBV reactivation in occult hepatitis, but systemic
chemotherapy has been reported as possible cause of OBI reac-
tivation (Raimondo et al., 2007; Saitta et al., 2013). The use of
prophylactic treatment in OBI patients is still debated and based
on viral serological status, type of cancer and chemoterapic drugs
(Sagnelli et al., 2014); actually, the use of antiviral therapy is rec-
ommended only for previously-mentioned patients at high risk of
reactivation, while it is indicated only ALT and HBV  DNA  monitor-
ing in the other clinical conditions (Squadrito et al., 2014; European
Association For The Study Of The Liver, 2009; Barclay et al., 2008).
Moreover, OBI may  be involved in the transmission of infection
through blood donations or organ transplantation; this situation
may  occurs when the donor is an OBI-carrier or when the blood
comes from a donor in the window period of acute HBV infection.
Moreover, the blood could be infected with variant viruses (so-
called S-escape mutants) not detectable by the available diagnostic
HBsAg assays (Candotti and Allain, 2009).
Other clinical implication is the possibility of HBV reactivation
in OBI-carriers. Finally, occult HBV infection plays a role in the
progression of chronic liver diseases and HCC, expecially in HCV
patients.
Clinicians should pay attention to the presence of OBI, par-
ticularly in immunosuppressed clinical conditions such as cancer
patients undergoing chemotherapy. Further studies are needed to
clarify clinical implications, preventive measures and the manage-
ment of occult infections in this category of patients.
8. HBV: to screen or not screen
There is no evidence in determining the beneﬁt of routine
screening for chronic HBV infection in patient undergoing cyto-
toxic and immunosuppressive chemotherapy. Major guidelines
(Hoofnagle, 2009; De la Revilla et al., 2013; European Association
For The Study Of The Liver, 2012; Lok and McMahon, 2009; Artz
et al., 2010; Weinbaum et al., 2008) (Table 2) recommend HBV
screening in HBV-infection high risk patients or if the immunosup-
pression caused by the treatment is expected to be high (Table 3).
Apart from this general recommendation, the guidelines, given the
inaccuracies in ascertaining risks for HBV infection, do not demon-
strate unanimous consent in offering HBV screening for all patients
undergoing chemotherapy. In fact, if patients receiving chemother-
apy are considered at high risk for reactivation of HBV per se, the
screening strategy should be universal. Furthermore, there is no
unanimous consent regarding serological tests: the majority of
guidelines recommend screening with HBsAg and anti-HBc, even
though the United States Centers of Disease Control and Prevention
(CDCP) consider a screening marker also anti-HBs.In North America and Western Europe the universal screening
for HBV infection with HBsAg and anti-HBc in patients with solid
tumours is probably not a cost-effective strategy (Day et al., 2011),
because of the low prevalence of HBV infection in general pop-
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Table 2
Principle guidelines recommendations for HBV in cancer patients.
Screening Prophylaxis Other recommendations
For whom? How? For whom? How long?
Lok and McMahon
(2009)
HBV-High risk patients before
chemotherapy or
immunosuppressive therapy
HBsAg and antiHBc HBV carriers ant the onset of cancer
chemotherapy or immunosuppressive therapy
For six months after the completion of
chemotherapy or immunosuppressive
therapy if baseline HBV DNA
<2000 UI/mL
Patients with HBV DNA baseline value
>2000 UI/mL  should continue
treatment as immunocompetent
patients.
If the treatment is expected to be short
(<1 year) and basal HBV DNA is low
lamivudine and telbivudine can be
used
If the treatment is expected to be
longer than 1 year tenofovir or
entecavir are preferred.
Avoid Interferon alpha because of the
bone marrow suppressive effect.
Artz et al. (2010) Insufﬁcient evidence to
determine the beneﬁts and the
harms of routine screening in
patients undergoing a
chemotherapic or
immunosuppressive treatment
HBV screening requires clinical
judgment
May be considered in HBV high
risk patients or if highly
immunosuppressive therapy is
planned
HBsAg
In some populations, testing for
antiHBc should also be considered
No evidence to support serologic
testing for antiHBs
In HBV chronic patients, an antiviral treatment
should be considered to reduce the risk of HBV
reactivation, although evidence is limited
– Screening and/or treating should not
delay the initiation of chemotherapy
European
Association For The
Study Of The Liver
(2012)
All candidates for
chemotherapy and
immunosoppressive treatment
HBsAg
antiHBc
HBsAg-positive patients should receive
pre-emptive antiviral treatment regardless of
HBV DNA level
HBsAg-negative, antiHBc positive patients
with detectable HBV DNA should be treated as
HBsAg positive patients
HBsAg-negative, antiHBc positive patients
with undetectable HBV DNA should be closely
monitored
– If the treatment is expected to be short
and basal HBV DNA is low lamivudine
and telbivudine can be used
If the treatment is expected to be
longer and basal HBV DNA tenofovir or
entecavir are preferred
Hoofnagle (2009) All patients undergoing cancer
chemotherapy and marked
immunosuppressive
treatments.
HBsAg
antiHBc
HBsAg-positive patients should be evaluated
for indications for HBV treatment and started
on  appropriate therapy
Inactive HBsAg carrier should receive antiviral
prophylaxis
HBsAg-negative, antiHBc positive patients with
undetectable HBV DNA should be considered
for antiviral treatment if aggressive or long
term chemotherapy/immunosuppression are
expected
In HBsAg-positive patients therapy
should continue for as long as required
for management of underlying chronic
disease
In other patients, prophylaxis should
continue for at least six months after
stopping chemotherapy
–
Weinbaum et al.
(2008)
All patients needing
immunosoppressive treatment
should undergo serologic
testing
HBsAg
antiHBc
antiHBs
All patients HBsAg-positive should receive
antiviral prophylaxis
Patients antiHBc-positive should be closely
monitored
– –
De la Revilla et al.
(2013)
All candidates for
chemotherapy should be
screened for before initiation
of therapy
For people living in areas of low
prevalence, it may  be sufﬁcient
to screen only those patients
who belong to high-risk groups
for HBV infection
HBsAg
antiHBc
All patients HBsAg-positive should receive
antiviral prophylaxis
HBV DNA positive patients should receive
antiviral prophylaxis according to HBV DNA
levels, as for HBsAg-positive patients
HBsAg-negative, antiHBc-positive with HBV
DNA test negative should be closely
monitored, but they should be considered for
antiviral treatment if aggressive or long term
chemotherapy/immunosuppression are
expected
Patients with HBV DNA levels > 2000
UI/mL  should be treated from one
week before initiating chemotherapy
until the same endpoints used for
immunocompetent patients
Patients with undectectable levels or
HBV DNA <2000 UI/mL should
continue treatment for 12 months after
cessation of chemotherapy
If the treatment is expected to be short
(<1 year) and basal HBV DNA is low
(<2000 UI/mL) lamivudine can be used
If  the treatment is expected to be
longer than 1 year or HBV DNA load is
>2000 UI/mL tenofovir or entecavir are
preferred.
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Table  3
Individuals at high risk for HBV infection.
People born in these countries at high or intermediate prevalence rates of infection:
Asia Africa Eastern Europe
South and Central America The Arctic European Mediterranean
South Paciﬁc Island Middle East
Other people recommended for screening
People born in low HBV prevalence countries not vaccinated and whose parents were born in high prevalence region
Sexual contacts with HBsAg-positive person
Inmates of prison
People who have multiple sexual partners
Patients infected with HCV and HIV
People that have injected drugs
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sPersons needing immunosuppressive treatment
lation and the expected risk of immunosuppression lower than
aematological patients.
Screening strategy may  be economically favourable in selected
atients and with a more simple serological marker, such as the use
f only HBsAg in adjuvant patients but further studies are needed
n order to consider this screening approach in clinical practice.
. What about HCV?
Hepatitis C virus (HCV) is one of the most important and
requent cause of chronic hepatitis, cirrhosis and hepatocellular
arcinoma. Prevalence of HCV infections is reported to be higher
n haematological malignancies, in particular in patients with a
iagnosis of Non-Hodgkin’s lymphoma.
In patients with solid cancer, the incidence of HCV-related liver
ysfunction is not well established because of limited data from
ew and retrospective studies (Morrow et al., 2010).
While the knowledge from previous research supports the man-
gement of hepatitis B during the treatment of breast cancer, little
nformation are available about treatment of patients with solid
ancer and chronic hepatitis C.
We  know that there is a close relation about HCV replication
nd immunosuppressive therapy, such as chemotherapy treat-
ent. Previous studies have shown a high rate of chemotherapy
iscontinuation and hepatotoxicity in patients with cancer and
CV-related hepatitis because of HCV reactivation due to an
ncreased HCV replication (Mahale et al., 2012).
HCV reactivation seems to be less common than HBV reactiva-
ion and is generally associated with a good outcome and less severe
edical consequences. Only a few deaths related to HCV reactiva-
ion during a chemotherapy treatment have been reported. Despite
his report, mortality rates of HCV-infected patients was similar to
hose of HBV-infected patients when a severe hepatitis due to a
iral reactivation developed (Torres and Davila, 2012).
Currently, no direct methods to predict patient’s risk of HCV
eactivation was point out.
Recommendations from CDCP suggest screening with a baseline
nti-HCV test, detecting speciﬁc antibodies against HCV (anti-HCV)
efore starting a chemotherapy treatment (Hwang et al., 2014).
HCV reactivation can be deﬁned as at least a threefold increase
n serum ALT level in a patient without liver involvement (liver
etastasis or primary tumor), who does not receive hepatotoxicity
rugs and have no systemic infections with the exception of HCV
De la Revilla et al., 2013).
The timing of HCV reactivation caused to a chemotherapy drug
dministration could vary. Acute exacerbation of HCV infection can
ccur during the cytotoxic treatment but usually it was observed
eeks or months after the last drug administration. No clinically
ymptomatic acute ALT or HCV RNA levels elevation was seen inthe most patients with HCV reactivation and usually liver enzymes
elevation was  mild and transient.
Patients with evidence of HCV infection (anti-HCV positive
and/or HCV RNA positive) should be closely monitored for liver
enzymes during and after chemotherapy. Monitoring ALT every 1–2
weeks and HCV RNA every 4 weeks during chemotherapy and for
at least 3 months after treatment end is recommended. If ALT level
increase more than 3 fold from baseline it’s necessary to establish a
close supervision in HCV RNA levels. If there is at least 1 log IU/mL
increase in HCV RNA compared to baseline viral load, it is reason-
able to consider discontinuation of chemotherapy if increasing of
liver enzymes precludes the use of cytotoxic drugs (De la Revilla
et al., 2013) (Fig. 3).
Increasing of liver enzymes should be associated with the
increase in HCV RNA levels, but this issue was poorly investi-
gated. Moreover, few studies demonstrated none direct correlation
between transaminase elevation and increase HCV-RNA levels dur-
ing chemotherapy in patients with breast cancer and HCV-related
hepatitis. These ﬁndings suggest that elevation of liver enzymes
could be related to liver toxicity caused to cytotoxic drugs (Miura
et al., 2013).
Currently no speciﬁc drugs for the prevention of HCV reac-
tivation are available in patients with solid tumors during a
chemotherapy treatment and only supportive therapy is consid-
ered. The risk of HCV reactivation could be reduced using lower
doses of cytotoxic and immunosuppressive drug, close monitoring
of liver enzymes and measuring HCV RNA levels early if a potential
viral reactivation was  supposed.
Anti-HCV therapy is avoided during chemotherapy because it
can worsen toxicity caused by cytotoxic drugs, in particular haema-
tological adverse effects.
In a retrospective cohort of patients with an early breast cancer
and HCV-related hepatitis, the treatment with anthracyclines with
or without taxane and trastuzumab was feasible even through in
approximately one-half of patients it was  required dose reductions
and delays during the therapy. The reason was  related to complica-
tions or side effects due to treatment and rather due to elevations
of transaminases (Morrow et al., 2010).
Data from literature revealed that in patients with solid can-
cer and HCV infection, the administration of targeted therapy
such as anti-HER therapy (trastuzumab, pertuzumab and lapatinib),
mTOR inhibitors (everolimus), anti-epidermal growth factor recep-
tor therapies (cetuximab, panitumumab) seemed safe (Yazici et al.,
2014).
Despite of poor data, chemotherapy and targeted therapy for
patients with a diagnosis of breast cancer and HCV infection appear
feasible and safety. Caution regarding neutropenia with or without
fever is recommended and the use of growth factors may be con-
sidered. Close monitoring of liver function during the treatment is
the critical step in the management of these patients.
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0. Conclusions: take stock of the situation!
During immunosuppressive treatments such as chemotherapy,
eactivation of HBV infection is a life-threatening complication that
an occur in HBV active or inactive carriers and in patients with OBI.
here is a clinical beneﬁt deriving from prophylactic antiviral treat-
ent in cancer patients at risk for HBV reactivation: lamivudine is
he drug of choice if DNA viral load is <2000 UI/mL, in other cases
enofovir or entecavir are indicated. On then other side, there is no
vidence in determining the beneﬁt of routine screening for chronic
BV infection in patient undergoing cytotoxic and immunosup-
ressive chemotherapy: the universal screening for HBV infection
ith HBsAg and anti-HBc in patients with solid tumours is proba-
ly not a cost-effective strategy. Underutilization of screening forCV-positive patients with cancer.
hepatitis B virus and of prophylaxis for reactivation is frequent in
clinical practice, but it can be lead to high rates of hospitalization,
discontinuation of chemotherapy, liver failure and death (Hwang
et al., 2015). HCV reactivation seems to be less common than HBV
reactivation and is generally associated with a good outcome and
less severe medical consequences and currently, no direct meth-
ods to predict patient’s risk of HCV reactivation was  point out. No
speciﬁc drugs for the prevention of HCV reactivation are available.
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